MC2 Therapeutics appoints Christopher S. Billis as Chief Commercial Officer
POSTED: October 25, 2018
Copenhagen, October 25th, 2018 – MC2 Therapeutics A/S, a clinical-stage dermatology and eye care company today announced that it has appointed Christopher S. Billis, an experienced healthcare executive within the ...
READ FULL ARTICLE >
MC2 Therapeutics A/S announces positive top-line results from Phase 3 clinical trial comparing MC2-01 Cream to Taclonex® in adults with psoriasis
POSTED: August 21, 2018
MC2-01 Cream demonstrates statistically significant superiority in both treatment success and patient reported treatment convenience compared to Taclonex® Topical Suspension. Both primary and secondary endpoints were met and a submission ...
READ FULL ARTICLE >
MC2 Therapeutics A/S announces completion of recruitment in US Phase 3 trial in Psoriasis Vulgaris
POSTED: April 2, 2018
- Topline results are expected in Q3 2018
Copenhagen, April 2nd, 2018 – MC2 Therapeutics A/S, a clinical-stage dermatology and eye care company today announced that the patient enrollment for the Phase ...
READ FULL ARTICLE >
